Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.

Autor:	Jost ST; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., Aloui S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., Evans J; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester, UK., Ashkan K; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.; Academic Health Science Centre, University of Manchester, Greater Manchester, UK., Sauerbier A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., Rizos A; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.; Academic Health Science Centre, University of Manchester, Greater Manchester, UK., Petry-Schmelzer JN; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., Gronostay A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., Fink GR; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich, Jülich, Germany., Visser-Vandewalle V; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, Cologne, Germany., Antonini A; Department of Neurosciences (DNS), Padova University, Padova, Italy., Silverdale M; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester, UK., Timmermann L; Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany., Martinez-Martin P; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain., Chaudhuri KR; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.; Academic Health Science Centre, University of Manchester, Greater Manchester, UK.; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; NIHR Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit, South London and Maudsley NHS Foundation Trust and King's College London, London, UK., Dafsari HS; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2024 Jan 02; Vol. 7 (1), pp. e2352177. Date of Electronic Publication: 2024 Jan 02.
DOI:	10.1001/jamanetworkopen.2023.52177
Abstrakt:	Importance: Deep brain stimulation of the subthalamic nucleus (STN-DBS) improves quality of life (QOL) in patients with advanced Parkinson disease (PD). However, controlled studies with more than 3 years of follow-up are lacking. Objective: To investigate the long-term effects of STN-DBS on QOL compared with standard-of-care medication (MED). Design, Setting, and Participants: In this prospective, observational, quasi-experimental, longitudinal nonrandomized controlled trial, 183 patients were screened for eligibility and 167 were enrolled from March 1, 2011, to May 31, 2017, at 3 European university centers. Propensity score matching for demographic and clinical characteristics was applied to 108 patients with PD (62 in the STN-DBS group and 46 in the MED group), resulting in a well-balanced, matched subcohort of 25 patients per group. Data analysis was performed from September 2022 to January 2023. Exposure: Treatment for PD of STN-DBS or MED. Main Outcomes and Measures: Assessments included Parkinson's Disease Questionnaire 8 (PDQ-8), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-activities of daily living (ADL) and motor complications, and levodopa-equivalent daily dose. Within-group longitudinal outcome changes, between-group differences, and correlations of change scores were analyzed. Results: The study population in the analysis included 108 patients (mean [SD] age, 63.7 [8.3] years; 66 [61.1%] male). At 5-year follow-up, PDQ-8 and ADL worsened only in the MED group (PDQ-8 change, -10.9; 95% CI, -19.0 to -2.7; P = .01; ADL change: -2.0; 95% CI, -3.1 to -0.8; P = .002), whereas both outcomes remained stable in the STN-DBS group (PDQ-8 change, -4.3; 95% CI, -13.2 to 4.7; P = .34; ADL change, -0.8; 95% CI, -2.5 to 1.0; P = .38). Changes in PDQ-8 and ADL correlated moderately (rs = .40, P = .008). Furthermore, STN-DBS outcomes were favorable for motor complications (median difference in change scores between STN-DBS and MED, -2.0; 95% CI, -4.0 to -1.0; P = .003), mobility (-1.0; 95% CI, -2.0 to 0; P = .03), and levodopa-equivalent daily dose reduction (-821.4; 95% CI, -1111.9 to -530.8; P < .001). Conclusions and Relevance: This study provides evidence of differences in QOL outcomes at 5-year follow-up between STN-DBS (stable) and MED (worsened), mainly driven by the favorable effect of STN-DBS on mobility (class IIb evidence). The association between changes in QOL and ADL, but not motor impairment or complications, highlights the relative importance of ADL outcomes for long-term DBS assessments. Trial Registration: German ClinicalTrials Registry: DRKS00006735.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu